SBIR/STTR Research Award

SBIR, Phase I (R43): Ultrasensitive Lateral Flow Assays Enabled by Fluorescent Nanodiamond Labels

Award identifier 66ced10177d7d0a68c555d840361bd539b36f5748b86c11a4be5c29bd6fe233cAwarding agency Department of Health and Human Services · Centers for Disease Control and Prevention

Award amount

$285,269

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Centers for Disease Control and Prevention
Recipient company
ADAMAS NANOTECHNOLOGIES INC
Proposal award date
2022-09-30
Contract end date
2023-09-29
UEI
XV1FPSTT7LF4
Solicitation number
PA-21-259
Topic code
CDC

Research abstract

Project Summary/Abstract:Lateral flow assays (LFAs) providing rapid on-site detection of medically significant analytes could be extremely valuable for high-volume, high-speed population screening necessary to minimize the economic and societal impact of epidemic outbreaks. However, LFA performance has been mostly limited to colorimetric binary diagnostics, primarily providing yes/no testing for clinically relevant analytes present at high concentrations (µM-nM) and cannot satisfy sensitivity requirements for reliable virus detection (fM-aM) which is presently achieved only using laboratory techniques (ELISA, PCR). Though signal amplification through fluorescence has steadily gained traction to improve sensitivity by 1-2 orders of magnitude in comparison with standard colorimetric tests, the inherent autofluorescence of materials used to construct LFA test strips interferes with test performance and introduces variability. By enabling rapid, attomolar sensitivity, fluorescence-based LFAs could facilitate a revolutionary shift in the analytical capability of point-of-care tests to provide quantitative actionable data to inform health authorities to launch timely responses. The pathway to this development involves advancement of the fluorescence detection system and material properties of the reporters. This proposal aims to strategically address both of these directions by advancing a recently emerged LFA platform based on fluorescent nanodiamond (FND) reporters. FNDs possess ideal features for an LFA reporter such as bright non- bleaching fluorescence and unsurpassed ruggedness. A prototype using FND as a novel LFA reporter was recently demonstrated by Debina Diagnostics in detecting Ebola virus glycoprotein at the picograms level, using a custom-made optoelectronic reader (Axxin, Inc.) and off-the-shelf 200 nm FND produced by Adámas Nanotechnologies. The most striking attribute of FND envisioned to improve FND-based LFA sensitivity by 2-3 orders of magnitude arises from the uniquely coupled magneto-optical properties of the particles, where nitrogen- vacancy (NV) color centers with an electron spin allow the intensity FND fluorescence to be modulated by an external magnetic field. Based on this unique property, the FND-related signal can be separated from background autofluorescence in the frequency domain through lock-in analysis which is widely used in signal processing to extract small periodic signals present below noise levels. Lock-in signal processing of FND can allow up to 100x increase in sensitivity, as was demonstrated in bioimaging including recent results in LFA. Adámas recently developed a method further increasing magnetic modulation contrast by 3-5 folds. In this proposal, Adámas and Debina join their efforts to tailor FND material properties in order to eliminate non-specific retention of particles on the LFA strip by modifying their physical (shape, size) and chemical (coating) properties, while optimizing brightness and magneto-optical properties (aim 1). After implementation and optimization of the lock-in analysis including interfacing the set-up with the opto-electronic reader (aim 2), we aim to demonstrate rt300x improvement in LOD of Ebola virus antigen and lt1pg LOD for detection of SARS-CoV-2 antigen (aim 3).

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2013–2024). Reported award amounts total $7,187,187. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.